Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpFinancial_Report.xls
10-Q - FORM 10-Q - Raptor Pharmaceutical Corpd270609d10q.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR8.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR6.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR2.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR9.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR3.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR1.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR12.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR18.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR11.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR17.htm
EX-32.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D. AND KIM R. TSUCHIMOTO - Raptor Pharmaceutical Corpd270609dex321.htm
EX-31.2 - CERTIFICATION OF KIM R. TSUCHIMOTO, CHIEF FINANCIAL OFFICER - Raptor Pharmaceutical Corpd270609dex312.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR5.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR14.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR13.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR19.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR10.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR15.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR16.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR4.htm
EX-31.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D., CHIEF EXECUTIVE OFFICER - Raptor Pharmaceutical Corpd270609dex311.htm
v2.4.0.6
Condensed Consolidated Statements Of Cash Flows (USD $)
3 Months Ended 75 Months Ended
Nov. 30, 2011
Nov. 30, 2010
Nov. 30, 2011
Cash flows from operating activities:      
Net loss $ (11,432,857) $ (10,120,777) $ (89,434,461)
Adjustments to reconcile net loss to net cash used in operating activities:      
Employee stock-based compensation expense 916,738 873,673 4,268,100
Consultant stock-based compensation expense   4,273 683,322
Fair value adjustment of common stock warrants 4,168,245 5,726,630 26,363,708
Amortization of intangible assets 36,500 38,375 587,458
Depreciation of fixed assets 8,669 19,685 509,442
Dividends, net of unrealized loss on short-term investments (18,461)   (18,461)
Write-off of intangible assets and other intellectual property     348,750
Amortization of capitalized finder's fee     102,000
Capitalized acquisition costs previously expensed     38,000
Changes in assets and liabilities:      
Prepaid expenses and other 85,738 96,063 (230,768)
Intangible assets     (150,000)
Deposits     (104,907)
Accounts payable 1,417,920 546,651 2,265,057
Accrued liabilities (590,867) (80,726) 977,660
Deferred rent (2,894) 11,825 21,136
Net cash used in operating activities (5,411,269) (2,884,328) (53,773,964)
Cash flows from investing activities:      
Purchase of fixed assets (2,520)   (549,046)
Cash acquired in 2009 Merger     581,391
Increase in restricted cash 1,132   (113,336)
Purchase of short-term investments (30,000,000)   (30,000,000)
Net cash used in investing activities (30,001,388)   (30,080,991)
Cash flows from financing activities:      
Proceeds from the sale of common stock 46,000,000   85,941,278
Proceeds from the sale of common stock under an equity line   899,977 11,639,568
Proceeds from the exercise of common stock warrants 1,956,939 348,706 17,854,438
Proceeds from the exercise of common stock options 39,691   208,300
Fundraising costs (3,014,363) (8,186) (7,341,327)
Proceeds from the sale of common stock to initial investors     310,000
Proceeds from bridge loan     200,000
Repayment of bridge loan     (200,000)
Principal payments on capital lease (968) (1,140) (18,478)
Net cash provided by financing activities 44,981,299 1,239,357 108,593,779
Foreign currency translation gain (loss) (8,473) 3,511 (6,569)
Net increase (decrease) in cash and cash equivalents 9,560,169 (1,641,460) 24,732,255
Cash and cash equivalents, beginning of period 15,172,086 [1] 16,953,524  
Cash and cash equivalents, end of period 24,732,255 15,312,064 24,732,255
Supplemental disclosure of non-cash financing activities:      
Warrants issued in connection with financing     16,310,414
Initial fair value of warrants issued to placement agents in connection with financings     208,660
Common stock and warrants issued in connection with reverse merger     4,417,046
Common stock issued as fee for equity line   46,121 827,637
Fair value of warrant liability reclassified to equity upon exercise 2,375,843   3,861,488
Acquisition of equipment in exchange for cap. lease     35,134
Notes receivable issued in exchange for common stock     110,000
Common stock issued for a finder's fee     102,000
Common stock issued in asset purchase     $ 2,898,624
[1] Derived from the Company's audited consolidated financial statements as of August 31, 2011.